Min Chen

Min Chen

Auto-generated profile, based on publicly available information

Min Chen

Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
JWJian Wu
Jian Wu
XZXing-Xing Zhang
Xing-Xing Zhang
ZXzou xi
zou xi
MWMin Wang
Min Wang
HWHong-Xing Wang
Hong-Xing Wang
SMSun qing Min
Sun qing Min

23 April 2019 in BMC Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
JZJin-Yong Zhou
Jin-Yong Zhou
MCMin Chen
Min Chen
CWCun-en Wu
Cun-en Wu
YZYu-wen Zhuang
Yu-wen Zhuang
YCYugen Chen
Yugen Chen
SLShen-Lin Liu
Shen-Lin Liu
The modified Si-Jun-Zi Decoction (SJZ), a Chinese medicine formula, is clinically used against multiple malignancies including colorectal cancer (CRC). This study aims to evaluate the effect of modified SJZ on CRC liver metastasis and identify the therapeutic mechanisms. Human CRC cells with GFP fluorescence were transplanted into Balb/c nude mice spleens. Modified SJZ, 5-fluorouracil or the combined treatment was given for 3 weeks. CRC liver metastasis was measured by fluorescence imaging and plasma cytokines were analyzed. Furthermore, the effects of administration time and doses for the modified SJZ were investigated in nude mice. Modified SJZ could increase the survival rate and reduce CRC liver metastasis in the nude mice model. Plasma GM-CSF level was elevated. Three weeks of treatment with the modified SJZ at the full dose (45 g/kg) could significantly increase the number of macrophages but not neutrophils in the spleen. These results indicate that modified SJZ can inhibit CRC liver metastasis by activating the innate immune system, providing a complementary and alternative therapy for CRC.


13 July 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
JZJin-Yong Zhou
Jin-Yong Zhou
CWCunen Wu
Cunen Wu
ZSZhaofeng Shen
Zhaofeng Shen
SLShenlin Liu
Shenlin Liu
ZXzou xi
zou xi
YZYu-wen Zhuang
Yu-wen Zhuang

19 January 2021 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
TWTing-Ting Wu
Ting-Ting Wu
JLJun Lu
Jun Lu
PZPei-Qiu Zheng
Pei-Qiu Zheng
SLShenlin Liu
Shenlin Liu
JWJian Wu
Jian Wu
ZXzou xi
zou xi
In the article titled “Yiqi Huayu Jiedu Decoction Inhibits the Invasion and Metastasis of Gastric Cancer Cells through TGF-β/Smad Pathway” [1], the clinical rationale for the study was not adequately supported because the statement that “Clinical study on large samples has shown that YHJD can obviously improve the quality of life of patients and prolong their survival” was unreferenced. The study was based on the outcomes of the project “Study on the individualized treatment based on Jianpi Yangwei for postoperative gastric cancer recurrence and metastasis (健脾养胃法为主的个体化治疗对胃癌术后复发转移干预方案的研究)” (200807022), which was funded by the National Administration of Traditional Chinese Medicine and ended in 2016. One of the authors, Dr. Liu, published a prospective cohort study on YHJD in gastric cancer in 2014 [2], updated in English in 2019 [3].

11 April 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YLYuan-Xiang Li
Yuan-Xiang Li
BMBai-Xiang Mu
Bai-Xiang Mu
HZHua-Jian Zhou
Hua-Jian Zhou
JQJun Qian
Jun Qian
JZJin-Yong Zhou
Jin-Yong Zhou
MCMin Chen
Min Chen
This study aims to develop nomograms for predicting overall survival (OS) and cancer-specific survival (CSS) in colorectal cancer (CRC) patients who did not receive primary site surgery but underwent chemotherapy. We analyzed data from 3,050 patients treated with chemotherapy without primary site surgery from 2010 to 2015, sourced from the Surveillance, Epidemiology, and End Results (SEER) database. The data were randomly divided into training and validation sets. Initial variable selection was performed using the least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression analysis was used to identify independent prognostic factors. Two nomograms were subsequently constructed based on these factors. Survival analysis was conducted using Kaplan-Meier plots and the log-rank test. We identified nine significant predictors of OS and CSS: age, marital status, primary site, grade, histology, T stage, M stage, tumor size, and CEA levels. The models for OS and CSS exhibited excellent predictability, with time-dependent area under the receiver operating characteristic curves (AUCs) exceeding 0.7. Calibration curves confirmed the accuracy of these predictions in the training and validation sets. Additionally, decision curve analysis (DCA) indicated that our models provide greater clinical benefit than traditional TNM staging. Notably, survival outcomes varied significantly across risk categories, affirming the models’ effective discrimination. For CRC patients who did not receive primary site surgery but underwent chemotherapy, this validated nomogram enables precision prognostication fundamentally shifting the paradigm from population-level TNM estimates to individualized risk-adaptive management.